Featured Research

from universities, journals, and other organizations

Targeting By Degradation: A New Way Forward For Treating Leukemias?

Date:
December 17, 2008
Source:
CNRS
Summary:
Used with success for treating acute promyelocytic leukemias, retinoic acid and arsenic oxide induce the differentiation of malignant cells. Is this differentiation responsible for the eradication of the disease? Researchers have managed to prove that this is not the case: the remissions are above all linked to the disappearance of the malignant stem cells responsible for the leukemia.

Used with success for treating acute promyelocytic leukemias, retinoic acid and arsenic oxide induce the differentiation of malignant cells. Is this differentiation responsible for the eradication of the disease? Researchers from a CNRS / Université Paris Diderot unit, working in the Hôpital Saint-Louis in Paris, have managed to prove that this is not the case: the remissions are above all linked to the disappearance of the malignant stem cells responsible for the leukemia.

Professor Hugues de Thé's team has recently demonstrated that this disappearance, induced by the treatment, is caused by the specific degradation of the protein responsible for the pathology. This therapeutic targeting constitutes a promising way forward that could be extended to other types of leukemia. Supported by the Ligue Contre le Cancer and by the Institut National du Cancer, this work was published on 23 November on the website of the journal Nature Medicine.

Acute promyelocytic leukemia (APL) is characterized by an excess of immature and malignant cells. This rare form of leukemia is the consequence of a chromosome translocation, uniquely found in leukemic cells. This chromosomal anomaly leads to the production of a fusion protein known as PML-RAR. Stemming from PML(1) and RAR(2) genes, this fusion protein is at the root of the pathology. It blocks the differentiation of promyelocytes, which remain immature. Incapable of disappearing naturally, the malignant cells accumulate in the bone marrow and in the blood.

At the moment there are two agents that are particularly effective for treating APL: a hormone, retinoic acid, and a poison, arsenic oxide. In use for a number of years altready, they bring about remission in patients.  Until now, this success has been explained by the fact that these drugs induced differentiation of the malignant cells into normal differentiated cells, which end up dying, which results in the normalization of the condition of the bone marrow. But can this differentiation explain the recoveries?

By modeling the response of these two agents, the team headed by Hugues de Thé(3) has partially answered this question. The researchers have for instance shown that the treatment of APL with these medicines brings about not only the differentiation of leukemic cells but, above all, the disappearance of the malignant stem cells responsible for the leukemia. This eradication is caused by the degradation of the fusion protein PML-RAR, itself induced by the cooperative action of the two drugs. Targeting the destruction of this protein is therefore a favored strategy for destroying leukemic stem cells.

This work represents a remarkable example of therapeutic targeting of a protein responsible for a cancer. It demonstrates that it is possible to specifically destroy cancerous stem cells by inducing the degradation of the proteins responsible for their survival. This new concept could be extended to other types of leukemia.

  1. PML for promyelocytic leukaemia, which modulates cell multiplication and cell death.
  2. RAR for retinoic acid receptor, which modulates the granular white blood cell differentiation program.
  3. Director of the “Molecular pathology and virology” research unit (CNRS / Université Paris Diderot) and Professor at the Hôpital St. Louis, AP/HP, Paris.

Story Source:

The above story is based on materials provided by CNRS. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rihab Nasr, Marie-Claude Guillemin, Omar Ferhi, Hassan Soilihi, Laurent Peres, Caroline Berthier, Philippe Rousselot, Macarena Robledo-Sarmiento, Valérie Lallemand-Breitenbach, Bernard Gourmel, Dominique Vitoux, Pier Paolo Pandolfi, Cécile Rochetteegly, Jun Zhu & Hugues de Thé. APL leukemia initiating cell eradication through cooperative cAMPRA-and arsenic-triggered PML/RARA degradation. Nature Medicine, 23 November 2008

Cite This Page:

CNRS. "Targeting By Degradation: A New Way Forward For Treating Leukemias?." ScienceDaily. ScienceDaily, 17 December 2008. <www.sciencedaily.com/releases/2008/12/081205213832.htm>.
CNRS. (2008, December 17). Targeting By Degradation: A New Way Forward For Treating Leukemias?. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2008/12/081205213832.htm
CNRS. "Targeting By Degradation: A New Way Forward For Treating Leukemias?." ScienceDaily. www.sciencedaily.com/releases/2008/12/081205213832.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) — The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins